**Guideline Page and Request** | **Panel Discussion** | **References** | **Vote**
---|---|---|---
**CHEM-A Internal Request:** Squamous Cell Cancers (Nasopharynx)
Suggestion was made to add carboplatin/5-FU as a chemotherapy option following chemoradiation.

Based on discussion and the noted reference, panel consensus was to revise the recommendation for chemoradiation followed by adjuvant chemotherapy to “Cisplatin + RT followed by cisplatin/5-FU (category 1) or carboplatin/5-FU”.


**CHEM-A Internal Request:**
Suggestion was made to add carboplatin/cetuximab and gemcitabine/vinorelbine as systemic therapy options.

Based on discussion and the noted references, the panel consensus was to add the following combination regimens to the list of systemic therapy options for recurrent, unresectable, or metastatic (incurable) disease:

- carboplatin/cetuximab (nasopharyngeal)
- gemcitabine/vinorelbine (nasopharyngeal)


**CHEM-A Internal Request:**
Suggestion was made to add capecitabine and vinorelbine to the list of single-agent systemic therapy options.

Based on discussion and the noted references, the panel consensus was to add the following single agents to the list of systemic therapy options for recurrent, unresectable, or metastatic (incurable) disease:

- capecitabine
- vinorelbine (non-nasopharyngeal)


**Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>21</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>20</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>19</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>